List view / Grid view
Airflow reduction and energy savings achieved in HVAC compared to conventional systems. The challenge of reducing HVAC energy consumption and operation costs without negatively affecting the quality of the finished products, ensuring cleanrooms always conform to required specifications
With the growing trend of injection device use at home, the device optimisation is essential to increase patient safety during self-administration.
Extensive portfolio of quality control solutions. Full regulatory compliance (USP, EP, JP Pharmacopoeias) of your sterility testing workflow.
A typical cleaning validation (CV) programme consists of three phases: Design, Validation and Continued Verification.
Syringe membrane filter selection/validation methods to assess analyte loss due to membrane filter adsorption in pharmaceutical quality control tests.
Why do E&L testing? Extractables & leachables studies enable drug sponsors to quantify and identify the risks of potentially toxic leachable impurities migrating into a drug solution from container closure systems, processing equipment or packaging.
This whitepaper from NSF looks at the key causes of drug shortages and what we can do to stop them.
New trends in automation and process control for sterilisation systems by integrating robotised loading and unloading technology.
Based on a study of the pharma industry’s remediation projects, this white paper from NSF looks at the key issues behind GMP non-conformance. It also includes questions to ask yourself when making changes to your processes and systems.
When performing chromatography separation, it is essential to determine the precise point when a substance is eluted from the column or cartridge to achieve optimal fractionation.
Mycoplasma are a form of bacteria that are characterized by the absence of a cell wall surrounding the cell membrane.
Successful completion of product development for active pharmaceutical ingredients (APIs) is a tremendously challenging task, in large part due to the amount of analytical data collected.
The US Food and Drug Administration (US FDA) defines complex generics as products having intricacy associated with an active pharmaceutical ingredient(s) (API), formulation process, route of delivery, or drug-device combination.
Partnering for product characterisation can streamline drug development and create efficiencies in moving from concept to clinic.
THE PARENTERAL Drug Association Technical Report No. 49 serves as a resource to help guide the development and evaluation of a cleaning validation programme.
